Schedule of estimated useful lives of property, plant and equipment

The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:


Production equipment		3 to 13 years
Office furniture and equipment		3 to 10 years
Buildings		39 years
Building improvements		5 to 15 years

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized

Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:


	For the three months ended June 30, 2025:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	4,859,995		294,829		3,325,272		9,581		8,489,677
North and South America sales (excluding U.S.)		973,020		—		772,416		—		1,745,436
Other international sales		95,514		7,948		97,608		9,550		210,620
Total	$	5,928,529	$	302,777	$	4,195,296	$	19,131	$	10,445,733


	For the three months ended June 30, 2024:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	4,631,773		333,389		42,561		5,848	$	5,013,571
North and South America sales (excluding U.S.)		601,000		—		59,040		6,240		666,280
Other international sales		256,133		400		87,680		5,300		349,513
Total	$	5,488,906	$	333,789	$	189,281	$	17,388	$	6,029,364


	For the six months ended June 30, 2025:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	10,998,270		638,662		4,267,790		17,265		15,921,987
North and South America sales (excluding U.S.)		1,526,520		—		772,416		—		2,298,936
Other international sales		363,878		7,947		138,608		9,550		519,983
Total	$	12,888,668	$	646,609	$	5,178,814	$	26,815	$	18,740,906


	For the six months ended June 30, 2024:
			Blood						Total
			Collection		EasyPoint^®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	10,185,082		700,998		755,432		13,226	$	11,654,738
North and South America sales (excluding U.S.)		755,537		96		59,040		6,240		820,913
Other international sales		828,612		143,860		174,704		5,900		1,153,076
Total	$	11,769,231	$	844,954	$	989,176	$	25,366	$	13,628,727

Schedule of diluted EPS under the treasury stock method

The calculation of diluted EPS under the treasury stock method included the following shares in the three and six month periods ending June 30, 2025 and 2024:


	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
Net loss	$	(87,471)	$	(14,164,640)	$	(10,588,187)	$	(13,735,256)
Preferred stock dividend requirements		(57,611)		(57,611)		(115,222)		(115,222)
Loss applicable to common shareholders	$	(145,082)	$	(14,222,251)	$	(10,703,409)	$	(13,850,478)
Average common shares outstanding		29,937,159		29,937,159		29,937,159		29,937,159
Average common and common equivalent shares outstanding — diluted		29,937,159		29,937,159		29,937,159		29,937,159
Basic loss per share	$	(0.00)	$	(0.48)	$	(0.36)	$	(0.46)
Diluted loss per share	$	(0.00)	$	(0.48)	$	(0.36)	$	(0.46)